Indaptus updates CFO, board and audit committee
Indaptus Therapeutics, Inc. reported leadership and board changes.
Rhea-AI Filing Summary
Indaptus Therapeutics, Inc. reported leadership and board changes. Chief Financial Officer Nir Sassi resigned effective April 1, 2026, and the company stated his resignation was not due to any disagreement regarding operations, policies, or practices.
On March 31, 2026, the board appointed Qinglai Lu, 48, as a director effective April 8, 2026 and determined he qualifies as an independent director under Nasdaq rules. The board also appointed Yu Ding, 51, as Chief Financial Officer effective April 1, 2026 after reviewing his qualifications.
The company adjusted its audit committee, with Matthew McMurdo resigning and Qinglai Lu and Jerome Jabbour joining the committee on March 31, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
CFO resignation effective date: April 1, 2026
New director effective date: April 8, 2026
New CFO appointment date: April 1, 2026
+3 more
6 metrics
CFO resignation effective date
April 1, 2026
Effective date of Nir Sassi’s resignation as Chief Financial Officer
New director effective date
April 8, 2026
Date when Qinglai Lu joins the Board of Directors
New CFO appointment date
April 1, 2026
Effective date of Yu Ding’s appointment as Chief Financial Officer
Age of new director
48 years
Age of newly appointed director Qinglai Lu
Age of new CFO
51 years
Age of newly appointed Chief Financial Officer Yu Ding
Audit committee changes date
March 31, 2026
Date of audit committee resignation and new appointments
Key Terms
Chief Financial Officer, independent, Audit Committee, Monetary Authority of Singapore, +1 more
5 terms
Chief Financial Officer financial
"Nir Sassi resigned as Chief Financial Officer on April 1, 2026."
A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.
independent regulatory
"The Board of Directors of the Company deemed Qinglai Lu to qualify as “independent” in accordance with the listing requirements of Nasdaq."
Audit Committee financial
"On March 31, 2026, Matthew McMurdo resigned as a member of the Audit Committee, and Qinglai Lu and Jerome Jabbour were appointed to the Audit Committee"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Monetary Authority of Singapore regulatory
"CPI Capital Management (Singapore) received regulatory approval from the Monetary Authority of Singapore to conduct fund management business in April 2025"
The Monetary Authority of Singapore is the main organization responsible for overseeing the country's money supply, banking system, and financial stability. It acts like a central bank, setting rules to keep the financial system safe and healthy. For investors, it matters because its policies influence interest rates, inflation, and the overall economic environment, impacting investment opportunities and risks.
Nasdaq Capital Market market
"Common Stock, $0.01 par value | | INDP | | Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What leadership changes did Indaptus Therapeutics (INDP) announce in this 8-K?
Indaptus Therapeutics announced that Chief Financial Officer Nir Sassi resigned effective April 1, 2026. The board simultaneously appointed Yu Ding as the new Chief Financial Officer and Qinglai Lu as a new independent director, alongside changes to the audit committee.
Why did Indaptus Therapeutics CFO Nir Sassi resign?
The company stated that Chief Financial Officer Nir Sassi resigned effective April 1, 2026, and that his resignation was not based on any disagreement with Indaptus on matters relating to operations, policies, or practices, suggesting an orderly leadership transition.
Who is the new Chief Financial Officer of Indaptus Therapeutics (INDP)?
Yu Ding, 51, was appointed Chief Financial Officer effective April 1, 2026. He has over 20 years of experience in capital management and strategic financial planning, including CFO roles at Grand Auto Service Group Co., Ltd. and Grand Baoxin Auto Group Limited in China and Hong Kong.
What is the background of new Indaptus director Qinglai Lu?
Qinglai Lu, 48, has more than 20 years of experience in corporate finance, banking, asset management, and distressed investments across Asia-Pacific. He is Managing Partner at Plunkett Capital and previously led financing solutions for Private Banking Asia at Goldman Sachs (Asia) LLC.
How did Indaptus Therapeutics change its audit committee in this filing?
On March 31, 2026, Matthew McMurdo resigned from the Audit Committee. The board appointed Qinglai Lu and Jerome Jabbour to the Audit Committee, updating its composition while keeping overall board oversight of financial reporting and controls in place.
Is new director Qinglai Lu considered independent under Nasdaq rules for INDP?
Yes. The board of Indaptus Therapeutics determined that Qinglai Lu qualifies as an independent director under the listing requirements of Nasdaq. This classification is important for meeting exchange governance standards related to board and committee composition.
AI-generated analysis. How Rhea-AI works. Not financial advice.
